DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes

Kizhakeyil, A., Zaini, N. B. M., Poh, Z. S., Wong, B. H. S., Loh, X., Ng, A. S., … Verma, N. K. (2021, December 1). DDX3X loss is an adverse prognostic marker in diffuse large B-cell lymphoma and is associated with chemoresistance in aggressive non-Hodgkin lymphoma subtypes. Molecular Cancer. BioMed Central Ltd. https://doi.org/10.1186/s12943-021-01437-0